Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases

Abstract Objective To describe the clinical efficacy of tixagevimab/cilgavimab in pre-exposure prophylaxis in patients at risk of severe coronavirus disease 2019 (COVID-19) and unresponsive to vaccination (anti-severe acute respiratory syndrome coronavirus 2 antibodies

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2024-05, Vol.63 (6), p.1632-1638
Main Authors: Thomas, Marion, Masson, Maeva, Bitoun, Samuel, Hamroun, Sabrina, Seror, Raphaele, Dupuy, Henry, Lazaro, Estibaliz, Richez, Christophe, Allanore, Yannick, Avouac, Jérôme
Format: Article
Language:English
Subjects:
Aged
Antibodies, Monoclonal, Humanized - therapeutic use
Autoimmune diseases
Autoimmune Diseases - drug therapy
Comorbidity
Connective tissue diseases
Coronaviruses
Corticosteroids
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 vaccines
Disease prevention
Female
Humans
Immunological tolerance
Immunosuppressive agents
Immunosuppressive Agents - therapeutic use
Incidence
Inflammatory diseases
Male
Methotrexate
Middle Aged
Pre-Exposure Prophylaxis - methods
Prophylaxis
Rheumatology
Rituximab
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Severity of Illness Index
Vaccination
Vasculitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective To describe the clinical efficacy of tixagevimab/cilgavimab in pre-exposure prophylaxis in patients at risk of severe coronavirus disease 2019 (COVID-19) and unresponsive to vaccination (anti-severe acute respiratory syndrome coronavirus 2 antibodies
ISSN:1462-0324
1462-0332
1462-0332
DOI:10.1093/rheumatology/kead449